The future of medical cannabis development in Europe
European Pharmaceutical Review
JULY 13, 2023
While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).
Let's personalize your content